作者
Megan Arthur, Nicole M Fett, Emile Latour, Heidi Jacobe, Elaine Kunzler, Stephanie Florez-Pollack, Jacob Houser, Shivani Sharma, Smriti Prasad, Alisa Femia, Marleigh J Stern, Lisa K Pappas-Taffer, Rebecca Gaffney, Anthony P Fernandez, Daniel Knabel, Adela Rambi Cardones, Nicole Leung, Anne Laumann, Jeong Min Yu, Jeffrey Zhao, Ruth Ann Vleugels, Elizabeth Tkachenko, Kelly Lo
发表日期
2020/5/1
期刊
JAMA dermatology
卷号
156
期号
5
页码范围
521-528
出版商
American Medical Association
简介
Importance
First-line systemic therapy for morphea includes methotrexate with or without systemic corticosteroids. When this regimen is ineffective, not tolerated, or contraindicated, a trial of mycophenolate mofetil (MMF) or mycophenolic acid (MPA)—referred to herein asmycophenolate—is recommended; however, evidence to support this recommendation remains weak.
Objective
To evaluate the effectiveness and tolerability of mycophenolate for the treatment of morphea.
Design, Setting, and Participants
A retrospective cohort study was conducted from January 1, 1999, to December 31, 2018, among 77 patients with morphea from 8 institutions who were treated with mycophenolate.
Main Outcomes and Measures
The primary outcome was morphea disease activity, severity, and response at 0, 3 to 6, and 9 to 12 months of mycophenolate treatment. A secondary outcome was whether mycophenolate was a well …
学术搜索中的文章
M Arthur, NM Fett, E Latour, H Jacobe, E Kunzler… - JAMA dermatology, 2020